Abstract Body: The prolonged alterations of the two-stages transducing process known as excitation-contraction coupling (ECC) ultimately leads to cardiac tissue remodeling and heart failure1. The use of a highly-sensitive and non-invasive cell-based biosensor can sharpen significantly the evaluation of the in vitroPRGHOV¶phenotype and novel cardiac drugs2. We have set up and tested an experimental system based on Atomic Force Microscopy (AFM) and MicroElectrode Array-based ElectroPhysiology (MEA-EP), to monitor the ECC components of human pluripotent stem cell-derived cardiac constructs, in the form of an embryoid body (EB)3. The experimental system was tested in basal condition and under drug trials against cardioactive species. The detected response confirmed an immature phenotype, showed multiple pacing sites in the cardiac constructs, and the modulation of the beating rate and force. On the road to implement a complete ECC monitoring system, the proposed combination boosts the informational content of a single analysis, thus leading to refined evaluation of in vitro models and novel cardiac drugs.Figure. Graphical representation of the combined electromechanical system for ECC monitoring References:1. Lou Q, Fedorov V V., Glukhov A V. et al., Circulation 123, 2011. 2. Pesl M, Pribyl J et al.,J Mol Recognit e2602 2016. 3. Pesl M, Pribyl J et al.,Biosens Bioelectron 85, 2016.